A Study on the Relationship between UGT2B7 Gene Polymorphism and Clinical Prognosis

Abstract

Breast cancer (BC) is the most common cancer diagnosis in women, often referred to as the "pink killer" [1], and its incidence ranks first among female malignancies, accounting for 25% of all cancer cases and 15% of all cancer deaths in the world [2]. With the improvement of medical level, the treatment methods of breast cancer have become relatively mature, including chemical therapy, adjuvant chemotherapy, neoadjuvant chemotherapy (mainly anthracycline and zisanchun drugs), endocrine therapy (tamoxifen, etc.), anti-estrogen drugs, aromatase inhibitors, etc. [3].In recent years, the role of UGT2B7 in drug metabolism and prognosis has been gradually discovered. To summarize the important role of UGT2B7 in prognosis diagnosis in recent years. In this paper, we search for qualified research by searching Pubmed, Uniprot and Chinese knowledge network. The data analysis and conclusion are helpful to the glucuronidation of many therapeutic drugs, including opioid drugs (such as codeine, morphine, naloxone), anticancer drugs (such as antitumor drugs: epirubicin, diclofenac, naproxen, etc.). In each treatment, the prognostic effect of UGT2B7 is gradually reflected, which is expected to be an important prognostic index.